Top Industry Leaders in the Sex Cord Gonadal Stromal Tumor Market
Latest Sex Cord-Gonadal Stromal Tumor Companies Updates:
OncoCell MDx launches OncoCell GIST test, a molecular diagnostic test for the detection of genetic mutations associated with SCGSTs: This test helps differentiate SCGSTs from other tumor types and guide treatment decisions
Bio-Rad Laboratories announces launch of QX200 Droplet Digital PCR (ddPCR) System, offering a more accurate and sensitive way to detect genetic mutations in SCGSTs: This technology potentially allows for better risk stratification and personalized treatment planning.
Foundation Medicine expands FoundationOne CDx panel to include genes associated with SCGSTs: This comprehensive genetic testing platform assists in identifying specific mutations and tailoring treatment accordingly.
Exact Sciences collaborates with academic institutions to develop liquid biopsy tests for SCGSTs: Early detection through blood-based testing could revolutionize diagnosis and management of these tumors.
List of Sex Cord-Gonadal Stromal Tumor Key companies in the market:
- Abbott
- Abcam plc
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Beckman, Dickinson and Company (BD)
- Bio SB Inc.
- BioCurex, BioModa, Inc.,
- Bio-Rad Laboratories, Inc.
- Boston Scientific Corporation
- Cell Signaling Technology, Inc.
- Clarient, Inc.